BIO-Europe 2026

Developing a cell or gene therapy, RNA therapeutic, or precision-oncology programme? Looking for a PCR strategy that scales from preclinical studies to the clinic?

With more than 25 years of multiplex PCR and dPCR experience, we support biopharma and diagnostics partners from assay development through to ISO 13485 manufacturing.

Here's how we can support your programme:

• qPCR and dPCR assay development and verification for cell and gene therapies
• RT-qPCR and dPCR analytics for RNA and oligonucleotide therapeutics
• PCR-based biomarker and patient-stratification assays, including RUO-to-CE-IVD transitions under IVDR
• ISO 13485 manufacturing of assays and complete kits for your QC teams and external study partners, including CMOs and CROs
• Early-phase preclinical sample testing as part of defined feasibility packages

Let's connect at BIO-Europe 2026:

Request a partnering meeting with Kathleen Clauß via partneringONE or connect with her directly on LinkedIn.